Stocks and Investing Stocks and Investing
Fri, February 11, 2022
Thu, February 10, 2022
Wed, February 9, 2022
Tue, February 8, 2022
Mon, February 7, 2022

Sumant Kulkarni Maintained (BIIB) at Strong Buy with Decreased Target to $305 on, Feb 7th, 2022


Published on 2024-10-27 19:35:09 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $335 to $305 on, Feb 7th, 2022.

Sumant has made no other calls on BIIB in the last 4 months.



There are 21 other peers that have a rating on BIIB. Out of the 21 peers that are also analyzing BIIB, 13 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Hold with Decreased Target to $235 on, Friday, February 4th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $244 on, Thursday, January 20th, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $275 on, Thursday, December 23rd, 2021
  • Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
  • Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021
  • Salveen Richter of "Goldman Sachs" Initiated at Hold and Held Target at $271 on, Monday, December 6th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, November 19th, 2021
  • Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $327 on, Friday, October 15th, 2021


These are the ratings of the 8 analyists that currently disagree with Sumant


  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $290 on, Friday, February 4th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $330 on, Friday, February 4th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $350 on, Wednesday, December 22nd, 2021
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $375 on, Thursday, October 21st, 2021
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $344 on, Friday, October 15th, 2021
  • Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021